Complete Omics Inc.

12/27/2021

Dear Team Members and Friends:

2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and patient care by advancing our multi-omics molecular diagnostic pipelines even further. In the year 2021, over 80 new research papers featuring Complete Omics’ technologies and platforms have been published.

2021 summer, Complete Omics started to offer cutting-edge multi-omics research services backed up by our top profile publications and patents. Now we are thrilled to work with over 30 pharmaceutical corporations and over 50 research labs worldwide to implement our Complete360® multi-omics molecular diagnostic pipeline and our Valid-NEO™ companion diagnostics pipeline. Hundreds of novel biomarkers and dozens of new drug targets are identified and quantified by us, and numerous treatment approaches are being developed based on our discoveries.

We expect massive new features to be added to our platforms over the next few years, and many exciting new discoveries ahead from ourselves and from the collaborations with scientists throughout the world.

Please follow our company’s page or contact us at [email protected] to learn more about how we can advance your research and patient care.

All of us at Complete Omics wish you a Merry Christmas and Happy New Year of 2022!

Best regards:
The Complete Omics Team

December 23, 2021 | BALTIMORE - Dear Team Members and Friends: 2021 has been an exciting year for Complete Omics - - we brought dramatic improvements to...

05/09/2021

When you look at your mother, you are looking at the purest love you will ever know. Happy mothers day to all mothers! Thanks for making this world so full of love by the touch of your motherhood. As researchers in molecular diagnostics, Complete Omics team is giving back by building a whole new set of revolutionary blood tests that could help every mom ensure her health easily at the lowest cost you will ever see. Stay tuned.

03/02/2021

For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer treatments through our multi-omics platform that we have accomplished and published on and .

Despite the challenges, stress, and worry in the pandemic, our scientist teams have been focusing on our original goal --- to create a healthier and happier world.

Please celebrate with us for the achievements we made in pushing forward the ultimate personalized cancer therapeutics, and we encourage you to follow us on our page and visit www.completeomics.com to learn more about our extraordinary works.

Publications:
Science Immunology: https://immunology.sciencemag.org/content/6/57/eabd5515
Science: https://science.sciencemag.org/content/early/2021/02/26/science.abc8697

[vc_row][vc_column][vc_column_text] [/vc_column_text][/vc_column][/vc_row][vc_row.

02/04/2021

“When you go through deep waters, I will be with you.” The strong love from moms, daughters, and from everyone to their loved ones suffering from cancers is always encouraging us and motivating us to work harder towards a cancer-free world.

01/19/2021

"Make a career of humanity. Commit yourself to the noble struggle for equal rights. You will make a better person of yourself, a greater nation of your country, and a finer world to live in." --- Martin Luther King, Jr.

Complete Omics is founded by minority and our dream is fulfilled by our highly diversified team members. We are dedicated to create multi-omics tests that are accessible to every single individual at the lowest or no cost, and to improve the life quality of EVERYONE. We are striving to make the dream of Dr. King come true in a new way, in our own way.

12/25/2020

Dear Colleagues and Friends:
It is the special time of a special year. I want to take this opportunity to thank everyone for all your efforts throughout the tough year. The success of our company is built on the efforts of all our employees. Thank you for the dedication and commitment that each one of you has shown to the company. We’ve come through a year that was filled with both challenges and opportunities. How reassuring it's been to know that we can count on all of you regardless of what faces us. On behalf of Complete Omics Inc, please allow me to extend my personal and genuine appreciation to each and every one of you for your valuable contributions to the team. Working with you this past year has been a pleasure and we’re proud to have you with us.

We offer our best wishes to you and your families at this special time as we all look forward to a successful new year of 2021!

Sincerely
Qing and Complete Omics board of directors

11/28/2020

Thanksgiving is an excellent time to spend with your loved ones and not think about working, but here at work, I want you to know that I am thankful for all team members in Complete Omics. Thank you for everything you do to make this a successful, terrific place to work. Happy Thanksgiving and Happy Holidays to you and yours!

11/20/2020

Throughout the history of the establishment of many of our pipelines, pancreatic cancer has been a big part of our target diseases. It's tough and daunting. However, we are pushing through steadily. We thank The Lustgarten Foundation for funding our basic research in Johns Hopkins for years and !

11/14/2020

Friday night routine at Complete Omics. I feel thrilled with our team's high productivity which is pushing us closer and closer to our targeted goals. I’d like to thank each one of you for the hard work and all the effort. I am glad that we make such a good team and are taking the company to another level!

11/10/2020

Here is another report last year about a technology that we developed specifically for personalized cancer therapeutics.

The method could prove useful both for studying tumor immunology and in the development of cancer immunotherapies, said one of the researchers.